1
|
Farah L, Scher N, Zerbib M, Martelli N, Borget I, Guetta T, Bauduceau O, Tolédano A. Analyse médicoéconomique de la radiothérapie stéréotaxique robotisée prostatique par comparaison à la prostatectomie totale robot-assistée en France. Cancer Radiother 2020. [DOI: 10.1016/j.canrad.2020.08.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
2
|
Pinar U, Anract J, Duquesne I, Dariane C, Chartier-Kastler E, Cussenot O, Desgrandchamps F, Hermieu JF, Irani J, de La Taille A, Méjean A, Mongiat-Artus P, Peyromaure M, Barrou B, Zerbib M, Rouprêt M. [Impact of the COVID-19 pandemic on surgical activity within academic urological departments in Paris]. Prog Urol 2020; 30:439-447. [PMID: 32430140 PMCID: PMC7211572 DOI: 10.1016/j.purol.2020.05.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 04/28/2020] [Accepted: 05/04/2020] [Indexed: 12/19/2022]
Abstract
Introduction En conséquence de la pandémie de COVID-19 en France, toute activité chirurgicale non urgente a dû être annulée à partir du 12 mars 2020. Afin d’anticiper la reprise des interventions décalées, une quantification de la réduction d’activité est nécessaire. L’objectif de l’étude était d’évaluer comparativement à 2019 la réduction d’activité chirurgicale urologique adulte pendant la pandémie de COVID-19. Matériel et méthodes Nous avons comparé le nombre d’interventions urologiques pratiquées dans les 8 services universitaires d’urologie de l’Assistance Publique – Hôpitaux de Paris (AP–HP) sur deux périodes comparables (14–29 mars 2019 et 12–27 mars 2020) à l’aide du logiciel de planification opératoire et du PMSI partagé par ces centres. L’intitulé d’intervention et le type de chirurgie ont été collectés et regroupées en 16 catégories. Résultats Une baisse de l’activité globale à l’AP–HP en urologie de 55 % entre 2019 et 2020 (995 et 444 interventions respectivement) a été constatée sur les 8 services. L’activité oncologique et les urgences ont diminué de 31 % et 44 %. L’activité de transplantation rénale, la chirurgie fonctionnelle et andrologique ont subi les plus fortes baisses d’activité par les interventions non oncologiques (−92 %, −85 % et −81 %, respectivement). Environ 1033 heures d’intervention devront être reprogrammées pour rattraper le programme opératoire annulé. Conclusion Le confinement et le report des interventions chirurgicales « non urgentes » ont entraîné une diminution drastique de l’activité chirurgicale au sein de l’AP–HP. Pendant cette période, les urologues ont été sollicités pour d’autres tâches mais doivent désormais s’atteler à organiser la période de reprise d’activité pour éviter une crise organisationnelle en urologique. Niveau de preuve 3.
Collapse
Affiliation(s)
- U Pinar
- GRC n(o) 5, PREDICTIVE ONCO-UROLOGY, hôpital Pitié-Salpêtrière, urologie, Sorbonne Université, AP-HP, 75013 Paris, France
| | - J Anract
- Servie d'urologie, hôpital Cochin, centre, université de Paris, AP-HP, 75014 Paris, France
| | - I Duquesne
- Servie d'urologie, hôpital Cochin, centre, université de Paris, AP-HP, 75014 Paris, France
| | - C Dariane
- Service d'urologie, hôpital européen Georges-Pompidou, centre, université de Paris, AP-HP, 75015 Paris, France
| | - E Chartier-Kastler
- Service d'urologie et de transplantation rénale, Hôpital Pitié-Salpêtrière, Sorbonne Université, AP-HP, 75013 Paris, France
| | - O Cussenot
- GRC n(o) 5, PREDICTIVE ONCO-UROLOGY, hôpital Tenon, urologie, Sorbonne Université, AP-HP, 75020 Paris, France
| | - F Desgrandchamps
- Service d'urologie, hôpital Saint-Louis, université de Paris, AP-HP, nord, 75010 Paris, France; CEA/SRHI, U976 HIPI, institut de recherche Saint-Louis, université de Paris, Paris, France
| | - J-F Hermieu
- Service d'urologie, hôpital Bichat, université de Paris, AP-HP, Nord, 75010 Paris, France
| | - J Irani
- Service d'urologie, hôpital Bicêtre, université Paris Saclay, AP-HP, 94270 Le Kremlin-Bicêtre, France
| | - A de La Taille
- Service d'urologie, hôpital Henri-Mondor, hôpitaux universitaires Henri-Mondor, AP-HP, 94010 Créteil, France
| | - A Méjean
- Service d'urologie, hôpital européen Georges-Pompidou, centre, université de Paris, AP-HP, 75015 Paris, France
| | - P Mongiat-Artus
- Service d'urologie, hôpital Saint-Louis, université de Paris, AP-HP, nord, 75010 Paris, France
| | - M Peyromaure
- Servie d'urologie, hôpital Cochin, centre, université de Paris, AP-HP, 75014 Paris, France
| | - B Barrou
- Service d'urologie et de transplantation rénale, Hôpital Pitié-Salpêtrière, Sorbonne Université, AP-HP, 75013 Paris, France
| | - M Zerbib
- Service d'urologie, centre, hôpital Cochin, université de Paris, AP-HP, 75014 Paris, France
| | - M Rouprêt
- GRC n(o) 5, PREDICTIVE ONCO-UROLOGY, hôpital Pitié-Salpêtrière, urologie, Sorbonne Université, AP-HP, 75013 Paris, France.
| |
Collapse
|
3
|
Sapetti J, Sakat J, Saad E, Zerbib M, Belas O, Doru-Pop C, Peyromaure M, Delongchamps N. Incontinence urinaire après énucléation endoscopique de la prostate au laser Holmium : fréquence, évolution, et facteurs prédictifs de survenue. Prog Urol 2019; 29:101-107. [DOI: 10.1016/j.purol.2018.12.008] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Revised: 10/07/2018] [Accepted: 12/12/2018] [Indexed: 11/24/2022]
|
4
|
Descazeaud A, Coloby P, Taille ADL, Kouri G, Mallet R, Rossi D, Rozet F, Zerbib M, Carrois F. Intérêt d’une évaluation systématique du traitement des symptômes du bas appareil urinaire dans la prise en charge d’une hypertrophie bénigne de la prostate en médecine générale. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
5
|
Le Goux C, Damotte D, Vacher S, Barry Delongchamps N, Sibony M, Terris B, Zerbib M, Bieche I, Pignot G. Identification d’une signature moléculaire prédictive du risque de progression des tumeurs de vessie n’infiltrant pas le muscle. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Joulia ML, Carton Vienet Legue E, Allard M, Huillard O, Peyromaure M, Zerbib M, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Pharmacokinetic/pharmacodynamic relationship of enzalutamide and its active metabolite N-desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Zhou Z, Xu L, Sennepin A, Federici C, Ganor Y, Tudor D, Damotte D, Barry Delongchamps N, Zerbib M, Bomsel M. The HIV-1 viral synapse signals human foreskin keratinocytes to secrete thymic stromal lymphopoietin facilitating HIV-1 foreskin entry. Mucosal Immunol 2018; 11:158-171. [PMID: 28443609 DOI: 10.1038/mi.2017.23] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Accepted: 03/01/2017] [Indexed: 02/04/2023]
Abstract
The complexity of signal transduction resulting from the contact of human immunodeficiency virus type 1 (HIV-1)-infected cells and mucosal cells has hampered our comprehension of HIV-1 mucosal entry. Such process is driven efficiently only by viral synapse contacts, whereas cell-free HIV-1 remains poorly infectious. Using CD4+ T-cells expressing only HIV-1 envelope inoculated on human adult foreskin tissues, we designed methodologies to identify the signals transduced in foreskin keratinocytes following HIV-1-envelope-dependent viral synapse formation. We find that the viral synapse activates the MyD88-independent TLR-4-nuclear factor (NfκB) signaling pathway in keratinocytes and the subsequent secretion of cytokines including thymic stromal lymphopoietin (TSLP), a cytokine linking innate and T-helper type 2-adaptive immune responses. Moreover, the viral synapse upregulates the non-coding microRNA miR-375, known to control TSLP, and transfection of keratinocytes with anti-miR-375 blocks significantly TSLP secretion. Thus, the secretion of TSLP by keratinocytes is induced by the viral synapse in a miR-375 controlled manner. At the tissue level, these signals translate into the epidermal redistribution of Langerhans cells and formation of conjugates with T-cells, recapitulating the initial events observed in human foreskin infection by HIV-1. These results open new possibilities for designing strategies to block mucosal HIV-1 transmission, the major pathway by which HIV-1 spreads worldwide.
Collapse
Affiliation(s)
- Z Zhou
- Mucosal Entry of HIV-1 and Mucosal Immunity, Infection, Immunity and Inflammation Department, Cochin Institute, Université Paris Descartes, Paris, France.,INSERM, U1016, Paris, France.,CNRS, UMR 8104, Paris, France
| | - L Xu
- Mucosal Entry of HIV-1 and Mucosal Immunity, Infection, Immunity and Inflammation Department, Cochin Institute, Université Paris Descartes, Paris, France.,INSERM, U1016, Paris, France.,CNRS, UMR 8104, Paris, France
| | - A Sennepin
- Mucosal Entry of HIV-1 and Mucosal Immunity, Infection, Immunity and Inflammation Department, Cochin Institute, Université Paris Descartes, Paris, France.,INSERM, U1016, Paris, France.,CNRS, UMR 8104, Paris, France
| | - C Federici
- INSERM, U1016, Paris, France.,CNRS, UMR 8104, Paris, France
| | - Y Ganor
- Mucosal Entry of HIV-1 and Mucosal Immunity, Infection, Immunity and Inflammation Department, Cochin Institute, Université Paris Descartes, Paris, France.,INSERM, U1016, Paris, France.,CNRS, UMR 8104, Paris, France
| | - D Tudor
- Mucosal Entry of HIV-1 and Mucosal Immunity, Infection, Immunity and Inflammation Department, Cochin Institute, Université Paris Descartes, Paris, France.,INSERM, U1016, Paris, France.,CNRS, UMR 8104, Paris, France
| | - D Damotte
- Anatomy and Pathological Cytology Service, GH Cochin-St Vincent de Paul, Paris, France
| | | | - M Zerbib
- Urology Service, GH Cochin-St Vincent de Paul, Paris, France
| | - M Bomsel
- Mucosal Entry of HIV-1 and Mucosal Immunity, Infection, Immunity and Inflammation Department, Cochin Institute, Université Paris Descartes, Paris, France.,INSERM, U1016, Paris, France.,CNRS, UMR 8104, Paris, France
| |
Collapse
|
8
|
Hennequin C, Rossi D, Zerbib M, Moreau J, Ruffion A, Neuzillet Y, Lebret T. EP-1314: Changes in hormonal therapy during the first 24 months of treatment: a longitudinal cohort study. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31749-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
9
|
Descazeaud A, Coloby P, Davin J, De La Taille A, Karsenty G, Kouri G, Rossi D, Pouteau J, Zerbib M. Validation du score visuel prostatique en images SVPI dans l’évaluation des symptômes du bas appareil urinaire associés à une hyperplasie bénigne de la prostate (550 patients). Prog Urol 2017; 27:176-183. [DOI: 10.1016/j.purol.2017.01.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Revised: 12/23/2016] [Accepted: 01/24/2017] [Indexed: 11/25/2022]
|
10
|
Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, Saidu NEB, Peyromaure M, Zerbib M, Narjoz C, Guibourdenche J, Thomas A, Vidal M, Goldwasser F, Blanchet B, Alexandre J. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer 2016; 72:54-61. [PMID: 28027516 DOI: 10.1016/j.ejca.2016.11.027] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Accepted: 11/09/2016] [Indexed: 12/25/2022]
Abstract
BACKGROUND Abiraterone (ABI) is a major oral agent for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients but its systemic exposure is subject to a large inter-individual variability. We aimed to explore the relationship between ABI trough plasma concentration and prostate-specific antigen (PSA) response in mCRPC patients and to identify the critical determinants for its activity. PATIENTS AND METHODS This is a monocentric prospective observational study in mCRPC patients treated with ABI. The plasmatic concentration of ABI at steady state was measured using liquid chromatography with fluorescence detection. The primary objective was to study the relationship between mean ABI plasma exposure (ABI Cmin) and 3-month PSA response. RESULTS From 2012 to 2016, 61 mCRPC patients were eligible for pharmacokinetic/pharmacodynamic assessment. Thirty-eight patients experienced PSA response (62%, [confidence interval {CI} 95% 50-78]). In univariate analysis, ABI Cmin was 1.5-fold higher in responders: 12.0 ng/mL (CI 95% 9.4-15.6) versus 8.0 ng/mL (CI 95% 5.8-11.6; P = 0.0015). In multivariate analysis, only ABI Cmin was independently associated with PSA response (odds ratio = 1.12 [CI 95% 1.01-1.25], P = 0.004). By receiver operating characteristic analysis, the optimal threshold for ABI Cmin was 8.4 ng/mL. Progression-free survival (PFS) was significantly higher in patients with ABI Cmin above 8.4 ng/mL (hazard ratio 0.55, [CI 95% 0.31-0.99], 12.2 [CI 95% 9.2-19.5] versus 7.4 [CI 95% 5.5-14.7] months otherwise, P = 0.044). CONCLUSIONS We showed that ABI trough concentration correlates with PSA response and PFS. Moreover, we could determine a cut-off value of plasmatic concentration for PSA response. Altogether, ABI concentration monitoring appears as a new approach to improve clinical outcome in mCPRC patients.
Collapse
Affiliation(s)
- E Carton
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France.
| | - G Noe
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - O Huillard
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - L Golmard
- Department of Genetics, Institut Curie, Paris, France
| | - J Giroux
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - A Cessot
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - N E B Saidu
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - M Peyromaure
- Department of Urology, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - M Zerbib
- Department of Urology, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - C Narjoz
- Biochemistry Unit, Georges Pompidou European Hospital, Paris Descartes University, AP-HP, Paris, France
| | - J Guibourdenche
- Hormonology Laboratory, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - A Thomas
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - M Vidal
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - F Goldwasser
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| | - B Blanchet
- Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France
| | - J Alexandre
- Department of Medical Oncology, Cochin Hospital, Paris Descartes University, CARPEM, AP-HP, Paris, France
| |
Collapse
|
11
|
Le goux C, Damotte D, Vacher S, Barry-delongchamps N, Sibony M, Terris B, Zerbib M, Bièche I, Pignot G. Valeur pronostique de PLEKHS1 dans la carcinogénèse urothéliale vésicale. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Le Goux C, Damotte D, Vacher S, Barry Delongchamps N, Sibony M, Terris B, Zerbib M, Bieche I, Pignot G. Identification d’une signature moléculaire pronostique composée de 3 gènes impliqués dans l’immunité dans les tumeurs urothéliales de vessie infiltrant le muscle. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Descazeaud A, Coloby P, Davin J, De la taille A, Karsenty G, Koury G, Rossi D, Zerbib M. Validation en urologie d’un score visuel prostatique en images (SVPI), dans l’évaluation des symptômes du bas appareil urinaire (SBAU) associés à une hypertrophie bénigne de la prostate (HBP). Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Le Goux C, Damotte D, Vacher S, Barry-Delongchamps N, Sibony M, Terris B, Zerbib M, Bieche I, Pignot G. Valeur pronostique de FOXP3 dans les tumeurs de vessie n’infiltrant pas le muscle. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Hennequin C, Rossi D, Zerbib M, Moreau J, Ruffion A, Neuzillet Y, Lebret T. Critères de modification de l’hormonothérapie des patients atteints de cancer de la prostate pris en charge par radiothérapie et hormonothérapie adjuvante. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Dabi Y, Rouscoff Y, Delongchamps NB, Sibony M, Saighi D, Zerbib M, Peyraumore M, Xylinas E. [Negative prognostic impact of female gender on oncological outcomes following radical cystectomy]. Prog Urol 2016; 26:83-8. [PMID: 26796347 DOI: 10.1016/j.purol.2015.12.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 10/25/2015] [Accepted: 12/11/2015] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To confirm gender specific differences in pathologic factors and survival rates of urothelial bladder cancer patients treated with radical cystectomy. PATIENTS AND METHODS We conducted a retrospective monocentric study on 701 patients treated with radical cystectomy and pelvic lymphadenectomy for muscle invasive bladder cancer. Impact of gender on recurrence rate, specific and non-specific mortality rate were evaluated using Cox regression models in univariate and multivariate analysis. RESULTS We collected data on 553 males (78.9%) and 148 females (21.1%) between 1998 and 2011. Both groups were comparable at inclusion regarding age, pathologic stage, nodal status and lymphovascular invasion. Mean follow-up time was 45 months (interquartile 23-73) and by that time, 163 patients (23.3%) had recurrence of their tumor and 127 (18.1%) died from their disease. In multivariable Cox regression analyses, female gender was independently associated with disease recurrence (RR: 1.73; 95% CI 1.22-2.47; P=0.02) and cancer-specific mortality (RR=2.50, 95% CI=1.71-3.68; P<0.001). CONCLUSION We confirmed female gender to be an independent negative prognosis factor for patients following a radical cystectomy and lymphadenectomy for an invasive muscle bladder cancer.
Collapse
Affiliation(s)
- Y Dabi
- Service d'urologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - Y Rouscoff
- Service d'urologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - N B Delongchamps
- Service d'urologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - M Sibony
- Service d'urologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - D Saighi
- Service d'urologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - M Zerbib
- Service d'urologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - M Peyraumore
- Service d'urologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - E Xylinas
- Service d'urologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| |
Collapse
|
17
|
Salomon L, Bastuji-Garin S, Soulie M, Devonec M, Boutin E, Mandron E, Benoit G, Rischmann P, Mottet N, Gasman D, Irani J, De la Taille A, Zerbib M, Vaesen C, Dore B, Lebret T, Colombel M, Lechevallier E, Gregoire L, Allory Y, Abbou C. [Not Available]. Prog Urol 2015; 25:793. [PMID: 26544349 DOI: 10.1016/j.purol.2015.08.154] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
| | | | - M Soulie
- Hôpital Rangueil, Toulouse, France
| | - M Devonec
- Centre hospitalier Lyon Sud, Lyon, France
| | - E Boutin
- CHU Henri-Mondor, Créteil, France
| | | | - G Benoit
- CHU Bicêtre, Le Kremlin-Bicêtre, France
| | | | - N Mottet
- CHU de Saint-Étienne, Saint-Étienne, France
| | - D Gasman
- Clinique de l'Yvette, Longjumeau, France
| | - J Irani
- CHU La Milétrie, Poitiers, France
| | | | | | - C Vaesen
- Groupe hospitalier Pitié Salpêtrière, Paris, France
| | - B Dore
- CHU de Poitiers, Poitiers, France
| | | | | | | | | | - Y Allory
- CHU Henri-Mondor, Créteil, France
| | - C Abbou
- CHU Henri-Mondor, Créteil, France
| |
Collapse
|
18
|
Durand-Zaleski I, Rabetrano H, Devonec M, Mandron E, Soulie M, De la Taille A, Benoit G, Mottet N, Gasman D, Dore B, Zerbib M, Vaessen C, Irani J, Lebret T, Colombel M, Lechevallier E, Bastuji-Garin S, Allory Y, Abbou C, Rischmann P, Salomon L. Résultats économiques de Propenlap, étude prospective multicentrique comparant les voies ouvertes et mini-invasives de la prostatectomie totale. Prog Urol 2015; 25:742. [DOI: 10.1016/j.purol.2015.08.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Pignot G, Le goux C, Bieche I, Vacher S, Barry de longchamps N, Sibony M, Zerbib M. Implication de la voie PD1/PDL1 et de la voie CTLA4/CD80 dans les tumeurs urothéliales. Prog Urol 2015; 25:762. [DOI: 10.1016/j.purol.2015.08.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Beurrier S, Lanz C, Elalouf V, Barry Delongchamps N, Sibony M, Saighi D, Zerbib M, Peyromaure M, Xylinas E. L’urétéroscopie diagnostique augmente le risque de récidive vésicale après néphro-urétérectomie totale. Prog Urol 2015; 25:804-5. [DOI: 10.1016/j.purol.2015.08.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
21
|
Rouscoff Y, Dabi Y, Mrini ME, Saighi D, Peyromaure M, Zerbib M, Xylinas E. Impact pronostique de l’indice de masse corporelle sur le devenir oncologique des patients atteints d’une tumeur de vessie infiltrant le muscle traités par cystectomie totale. Prog Urol 2014; 24:805. [DOI: 10.1016/j.purol.2014.08.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Such M, Delongchamps NB, Saighi D, Peyromaure M, Zerbib M, Xylinas E. Marges chirurgicales positives après cystectomie totale : une issue fatale ? Prog Urol 2014; 24:807. [DOI: 10.1016/j.purol.2014.08.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Dabi Y, Rouscoff Y, Mrini ME, Delonchamps NB, Saighi D, Peyromaure M, Zerbib M, Xylinas E. Impact pronostique du sexe féminin sur le devenir oncologique des patients atteints d’une tumeur de vessie infiltrant le muscle traités par cystectomie totale. Prog Urol 2014; 24:805. [DOI: 10.1016/j.purol.2014.08.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Abakka N, Shahrokh S, El Mrini M, Saighi D, Peyromaure M, Zerbib M, Xylinas E. Intérêt de l’instillation postopératoire précoce de mitomycine C (IPOP) dans les tumeurs de vessie n’infiltrant pas le muscle : vers un âge limite ? Prog Urol 2014; 24:848. [DOI: 10.1016/j.purol.2014.08.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Descazeaud A, Coloby P, Davin JL, De la Taille A, Karsenty G, Kouri G, Rossi D, Jaquet D, Zerbib M. Validation en médecine générale d’un score visuel prostatique en images (SVPI), dans l’évaluation des symptômes du bas appareil urinaire (SBAU) associés à une hypertrophie bénigne de la prostate (HBP). Prog Urol 2014; 24:789. [DOI: 10.1016/j.purol.2014.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Bruzzi M, Le Goux C, Pignot G, Amsellem-Ouazana D, Vieillefond A, Patard JJ, Zerbib M. [Pronostic value of parenchyma renal invasion of pT3 upper tract urinary carcinoma]. Prog Urol 2014; 24:556-62. [PMID: 24975790 DOI: 10.1016/j.purol.2013.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2013] [Revised: 12/01/2013] [Accepted: 12/18/2013] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Upper tract urinary carcinoma (UTUC) pT3 tumors are a heterogeneous entity including tumors invading the renal parenchyma, tumors with peripelvic fat invasion or peri-ureteral fat invasion. The aim of this study was to evaluate the prognostic significance of these three different groups of pT3 tumors. PATIENTS AND METHODS Between 1998 and 2012, 205 patients with UTUC were operated in two centers, including 52 patients with pT3 tumor stage. pT3 tumors were divided into three groups: peri-ureteral fat invasion (pT3U, n = 16), peripelvic fat invasion (pT3G, n = 21), and renal parenchyma invasion (pT3P, n = 15). The prognostic significance of the type of tumor infiltration was evaluated on specific and disease-free survival. RESULTS Median follow-up was 18.9 months [6-133.4]. In univariate analysis, renal parenchyma invasion was associated with a better prognostic in both specific (P = 0.026) and disease-free survival (P = 0.031) compared with peripelvic or peri-ureteral fat invasion. Mutivariate analysis retained the pT3 subgroup as an independant prognostic factor in both specific and disease-free survival (P = 0.02). CONCLUSION pT3 tumors with renal parenchyma invasion had a better prognosis than those with peripelvic or peri-ureteral fat invasion. The heterogeneity of the pT3 group should be taken into account to improve the care of patients.
Collapse
Affiliation(s)
- M Bruzzi
- Service d'urologie, hôpital Bicêtre, université Paris-Sud Paris XI, 94270 Le Kremlin-Bicêtre, France
| | - C Le Goux
- Service d'urologie, hôpital Bicêtre, université Paris-Sud Paris XI, 94270 Le Kremlin-Bicêtre, France.
| | - G Pignot
- Service d'urologie, hôpital Bicêtre, université Paris-Sud Paris XI, 94270 Le Kremlin-Bicêtre, France
| | - D Amsellem-Ouazana
- Service d'urologie, hôpital Cochin, université Paris Descartes Paris V, 75014 Paris, France
| | - A Vieillefond
- Service d'anatomopathologie, hôpital Cochin, 75014 Paris, France
| | - J-J Patard
- Service d'urologie, hôpital Bicêtre, université Paris-Sud Paris XI, 94270 Le Kremlin-Bicêtre, France
| | - M Zerbib
- Service d'urologie, hôpital Cochin, université Paris Descartes Paris V, 75014 Paris, France
| |
Collapse
|
27
|
Xylinas E, Robinson B, Kluth L, Volkmer B, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson R, Boorjian S, Shariat S. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol 2014; 40:121-7. [DOI: 10.1016/j.ejso.2013.08.023] [Citation(s) in RCA: 103] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 08/06/2013] [Accepted: 08/20/2013] [Indexed: 01/16/2023] Open
|
28
|
Elalouf V, Klap J, Delongchamps NB, Conquy S, Sibony M, Saighi D, Peyromaure M, Flam T, Zerbib M, Xylinas E. Facteurs pronostiques des tumeurs de la voie excrétrice urinaire supérieure. Prog Urol 2013; 23:1382-8. [DOI: 10.1016/j.purol.2013.04.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Revised: 04/04/2013] [Accepted: 04/08/2013] [Indexed: 11/26/2022]
|
29
|
Barry Delongchamps N, Beuvon F, Bouazza N, Khoury G, Peyromaure M, Zerbib M, Cornud F. Volume tumoral à cibler en cas de thérapie focale pour cancer localisé de la prostate: l’IRM multiparamétrique permet-elle une estimation fiable ? Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
30
|
Peyromaure M, Desfontaines J, Barry Delongchamps N, Saïghi D, Debré B, Flam T, Zerbib M. Dépistage du cancer prostatique : le point de vue des patients ayant eu une prostatectomie totale. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Xylinas E, Zerbib M, Shariat S. Validation externe des tables de l’EORTC et du score CUETO pour la prédiction de la récidive et de la progression tumorale des tumeurs de la vessie n’infiltrant pas le muscle. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, Shariat SF. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013; 109:1460-6. [PMID: 23982601 PMCID: PMC3776972 DOI: 10.1038/bjc.2013.372] [Citation(s) in RCA: 168] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2013] [Revised: 06/13/2013] [Accepted: 06/22/2013] [Indexed: 11/24/2022] Open
Abstract
Background: The European Organization for Research and Treatment of Cancer (EORTC) risk tables and the Spanish Urological Club for Oncological Treatment (CUETO) scoring model are the two best-established predictive tools to help decision making for patients with non-muscle-invasive bladder cancer (NMIBC). The aim of the current study was to assess the performance of these predictive tools in a large multicentre cohort of NMIBC patients. Methods: We performed a retrospective analysis of 4689 patients with NMIBC. To evaluate the discrimination of the models, we created Cox proportional hazard regression models for time to disease recurrence and progression. We incorporated the patients calculated risk score as a predictor into both of these models and then calculated their discrimination (concordance indexes). We compared the concordance index of our models with the concordance index reported for the models. Results: With a median follow-up of 57 months, 2110 patients experienced disease recurrence and 591 patients experienced disease progression. Both tools exhibited a poor discrimination for disease recurrence and progression (0.597 and 0.662, and 0.523 and 0.616, respectively, for the EORTC and CUETO models). The EORTC tables overestimated the risk of disease recurrence and progression in high-risk patients. The discrimination of the EORTC tables was even lower in the subgroup of patients treated with BCG (0.554 and 0.576 for disease recurrence and progression, respectively). Conversely, the discrimination of the CUETO model increased in BCG-treated patients (0.597 and 0.645 for disease recurrence and progression, respectively). However, both models overestimated the risk of disease progression in high-risk patients. Conclusion: The EORTC risk tables and the CUETO scoring system exhibit a poor discrimination for both disease recurrence and progression in NMIBC patients. These models overestimated the risk of disease recurrence and progression in high-risk patients. These overestimations remained in BCG-treated patients, especially for the EORTC tables. These results underline the need for improving our current predictive tools. However, our study is limited by its retrospective and multi-institutional design.
Collapse
Affiliation(s)
- E Xylinas
- 1] Department of Urology, Weill Cornell Medical College, New York, NY, USA [2] Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 2013; 107:1826-32. [PMID: 23169335 PMCID: PMC3504939 DOI: 10.1038/bjc.2012.464] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND In pT1-T3N0 urothelial carcinoma of the bladder (UCB) patients, multi-modal therapy is inconsistently recommended. The aim of the study was to develop a prognostic tool to help decision-making regarding adjuvant therapy. METHODS We included 2145 patients with pT1-3N0 UCB after radical cystectomy (RC), naive of neoadjuvant or adjuvant therapy. The cohort was randomly split into development cohort based on the US patients (n=1067) and validation cohort based on the Europe patients (n=1078). Predictive accuracy was quantified using the concordance index. RESULTS With a median follow-up of 45 months, 5-year recurrence-free and cancer-specific survival estimates were 68% and 73%, respectively. pT-stage, ge, lymphovascular invasion, and positive margin were significantly associated with both disease recurrence and cancer-specific mortality (P-values ≤ 0.005). The accuracies of the multivariable models at 2, 5, and 7 years for predicting disease recurrence were 67.4%, 65%, and 64.4%, respectively. Accuracies at 2, 5, and 7 years for predicting cancer-specific mortality were 69.3%, 66.4%, and 65.5%, respectively. We developed competing-risk, conditional probability nomograms. External validation revealed minor overestimation. CONCLUSION Despite RC, a significant number of patients with pT1-3N0 UCB experience disease recurrence and ultimately die of UCB. We developed and externally validated competing-risk, conditional probability post-RC nomograms for prediction of disease recurrence and cancer-specific mortality.
Collapse
Affiliation(s)
- E Xylinas
- Department of Urology, Weill Cornell Medical College, Starr 900, 525 East 68th Street, Box 94, New York, NY 10065, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Le Goux C, Pignot G, Amsellem-Ouazana D, Vieillefond A, Peyromaure M, Flam T, Debré B, Zerbib M. [Pronostic value of ureteral location of upper tract urinary carcinoma]. Prog Urol 2013; 23:399-404. [PMID: 23628098 DOI: 10.1016/j.purol.2013.01.025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2012] [Revised: 01/30/2013] [Accepted: 01/31/2013] [Indexed: 11/25/2022]
Abstract
OBJECTIVES The aim of this study was to evaluate the prognostic significance of the ureteral location of the upper tract urinary carcinoma (UTUC). PATIENTS AND METHODS Between January 1998 and December 2007, 161 patients with UTUC were operated in our center. Tumors were located on renal pelvis in 51% of cases, on the ureter in 34% of cases and in both locations in 15% of cases. Nephroureterectomy was performed in 79.5% of cases (128/161) whereas a conservative treatment was performed in 20.5% of cases (33/161). RESULTS In our series, 29.8% of patients had primary bladder cancer and 14.3% had synchronous bladder tumor. At a median follow-up of 42.5 months, 38.6% of patients developed bladder recurrence and 4.8% developed controlateral upper tract tumor. In multivariate analysis, ureteral location and existence of synchronous bladder tumor were independent prognostic factors of bladder recurrence (P=0.009 and P=0.025, respectively). Multivariate analysis retained T-stage and ureteral location as independent prognostic factors in both overall and disease-free survival (P=0.002 and P=0.0008 respectively for ureteral location). CONCLUSION Ureteral location was an independent prognostic factor of bladder recurrence and was associated with a poorer prognosis.
Collapse
Affiliation(s)
- C Le Goux
- Service d'urologie, hôpital Cochin, université Paris-V - Paris Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, Ropert S, Delongchamps NB, Zerbib M, Goldwasser F. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013; 108:1034-41. [PMID: 23462722 PMCID: PMC3619075 DOI: 10.1038/bjc.2013.58] [Citation(s) in RCA: 171] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Little is known on factors predicting sunitinib toxicity. Recently, the condition of low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in metastatic renal cell cancer (mRCC) patients treated with sorafenib. We investigated whether sarcopenia could predict early dose-limiting toxicities (DLTs) occurrence in mRCC patients treated with sunitinib. METHODS Consecutive mRCC patients treated with sunitinib were retrospectively reviewed. A DLT was defined as any toxicity leading to dose reduction or treatment discontinuation. Body composition was evaluated using CT scan obtained within 1 month before treatment initiation. RESULTS Among 61 patients eligible for analysis, 52.5% were sarcopenic and 32.8% had both sarcopenia and a body mass index (BMI)<25 kg m(-2). Eighteen patients (29.5%) experienced a DLT during the first cycle. Sarcopenic patients with a BMI<25 kg m(-2) experienced more DLTs (P=0.01; odds ratio=4.1; 95% CI: (1.3-13.3)), more cumulative grade 2 or 3 toxicities (P=0.008), more grade 3 toxicities (P=0.04) and more acute vascular toxicities (P=0.009). CONCLUSION Patients with sarcopenia and a BMI<25 kg m(-2) experienced significantly more DLTs during the first cycle of treatment.
Collapse
Affiliation(s)
- O Huillard
- Department of Medical Oncology, University Paris Descartes, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Barry Delongchamps N, Conquy S, Zerbib M, Peyromaure M. Pose d’implants Urolift® pour hyperplasie bénigne de la prostate : technique opératoire et cas clinique. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Xylinas E, Rink M, Margulis V, Lotan Y, Zerbib M, Shariat S. Outil de prédiction de la survie sans récidive et de la survie spécifique des patients pT1-T3N0 après cystectomie radicale. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
38
|
-Lebret T, Davin JL, Hennequin C, Latorzeff I, Mignard JP, Moreau JL, Rossi D, Ruffion A, Zerbib M, Culine S. Résultats d’une étude prospective française (CHRONO) évaluant le renouvellement d’un traitement par GnRH chez des patients atteints d’un cancer de la prostate. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
39
|
Bigot P, Hetet JF, Fardoun T, Xylinas E, Ploussard G, Ouzaid I, Audenet F, Long JA, Bastien L, Hoarau N, Roupret M, Mongiat-artus P, Verhoest G, Zerbib M, Ravery V, Baumert H, Bensalah K, Escudier B, Grenier N, Paparel P, Rioux-leclercq N, Bernhard JC, Azzouzi AR, Patard JJ. Résultats oncologiques de la néphrectomie partielle pour les tumeurs rénales de plus de 7cm : étude multicentrique rétrospective française. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-ouazana D, Bieche I. Identification d’une signature moléculaire de 3-miARNs predictive de l’aggressivité et du pronostic des tumeurs de vessie infiltrant le muscle. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Barry De Longchamps N, Cornud F, Schull A, Bouazza N, Flam T, Zerbib M, Peyromaure M. IRM avant biopsies de la prostate : comparaison des biopsies randomisées et ciblées en utilisant trois techniques différentes de fusion d’image. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Xylinas E, Rink M, Margulis V, Lotan Y, Zerbib M, Shariat S. Impact de la consommation tabagique sur le devenir des patients présentant une tumeur de vessie n’infiltrant pas le muscle primaire. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Bernhard J, Mejean A, Pignot G, Zini L, Lang H, Zerbib M, Crepel M, Rigaud J, Salomon L, Vaessen C, Bellec L, Martin X, Bigot P, Bruyere F, Berger J, Gimel P, Hubert J, Pfister C, Mottet N, Patard J. Quel est l’usage de la néphrectomie partielle en France ? Données de l’étude Néphron. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
44
|
Zerbib M. Résultats de l’enquête observationnelle action : mesures d’accompagnement non urologiques d’une hormonothérapie par leuproréline pour cancer de la prostate en pratique quotidienne. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
45
|
Pignot G, Salomon L, Neuzillet Y, Masson-Leconte A, Lunardi P, Rischmann P, Legoux C, Zerbib M, Lebacle C, Patard JJ, Lacarriere E, Champy C, Roupret M, Comperat E, Molimard B, Houlgatte A, Gres P, Hetet JF, Colls P, Soulie M, Pfister C. Prévalence et impact pronostique des cancers de prostate sur pièce de cysto-prostatectomie : résultats préliminaires d’une étude multicentrique française. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Coloby P, Boccon-Gibod L, Coulange C, Culine S, Davin JL, Richaud P, Zerbib M, Soulié M. [Prostate cancer, androgenic suppression and associated conditions. Practical refinement by a panel of multidisciplinary experts for patient integral management]. Prog Urol 2012; 22 Suppl 2:S29-30. [PMID: 23098787 DOI: 10.1016/s1166-7087(12)70033-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Xylinas E, Rink M, Margulis V, Lotan Y, Zerbib M, Shariat S. Facteurs pronostiques de survie des patients ayant des marges chirurgicales positives après cystectomie radicale pour tumeur de vessie. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Delongchamps NB, Conquy S, Defontaines J, Zerbib M, Peyromaure M. [Intra-prostatic UroLift(®) implants for benign prostatic hyperplasia: preliminary results of the four first cases performed in France]. Prog Urol 2012; 22:590-7. [PMID: 22920338 DOI: 10.1016/j.purol.2012.05.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2012] [Revised: 05/02/2012] [Accepted: 05/08/2012] [Indexed: 10/28/2022]
Abstract
OBJECTIVES To evaluate the feasibility, tolerance and short-term efficacy of intra-prostatic UroLift(®) implants in four patients with symptomatic benign prostatic hyperplasia. PATIENTS AND METHOD Four patients with symptomatic BPH, already treated with alpha-blockers, were consecutively treated with intra-prostatic UroLift(®) implants under general anaesthesia. A bladder catheter was placed postoperatively. Alpha-blocker therapy was withdrawn 7 days postoperatively. The clinical and morphological characteristics of the patients were noted. Low urinary tract (IPSS) and sexual symptoms (IIEF5, MSHQ-EjD), maximum urinary flow rate and post voiding residual volume were evaluated preoperatively and at 1 month. RESULTS Median age was of 69 [52-74] years old and median prostatic volume of 50 cm(3) [40-80]. Median procedure time was of 11 minutes [6-15]. Intra- and postoperative outcomes were uneventful. At 1 month, the mean IPSS and IPSS-QOL improvement were of 46 % and 58 %, respectively. One patient reported no improvement in his urinary and sexual symptoms. In the other three patients, the maximum urinary flow rate was improved, the post voiding residual improved in two patients and similar in one. No alteration in erection or ejaculation functions was reported. CONCLUSIONS In our initial experience, intra-prostatic UroLift(®) implant procedure seemed feasible, efficacious for LUTS and well tolerated, especially concerning sexual outcomes. Further study of the UroLift(®) implant in France is currently being planned.
Collapse
Affiliation(s)
- N B Delongchamps
- Service d'urologie, université Paris Descartes, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| | | | | | | | | |
Collapse
|
49
|
Cornud F, Rouanne M, Beuvon F, Eiss D, Flam T, Liberatore M, Zerbib M, Delongchamps N. Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: Should we reconsider the indirects signs of extracapsular extension according to the D’Amico tumor risk criteria? Eur J Radiol 2012; 81:e591-7. [DOI: 10.1016/j.ejrad.2011.06.056] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2011] [Revised: 06/28/2011] [Accepted: 06/29/2011] [Indexed: 11/26/2022]
|
50
|
Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R, Amsellem-Ouazana D, Bieche I. Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer 2012; 106:1177-86. [PMID: 22361633 PMCID: PMC3304423 DOI: 10.1038/bjc.2012.55] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2011] [Revised: 01/27/2012] [Accepted: 02/03/2012] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND The Hedgehog (Hh) signalling pathway functions as an organiser in embryonic development. Recent studies have shown constitutive activation of this pathway in various malignancies, but its role in bladder cancer remains poorly studied. METHODS Expression levels of 31 genes and 9 microRNAs (miRNAs) involved in the Hh pathway were determined by quantitative real-time RT-PCR in 71 bladder tumour samples (21 muscle-invasive (MIBC) and 50 non-muscle-invasive (NMIBC) bladder cancers), as well as in 6 bladder cancer cell lines. RESULTS The SHH ligand gene and Gli-inducible target genes (FOXM1, IGF2, OSF2, H19, and SPP1) were overexpressed in tumour samples as compared with normal bladder tissue. SHH overexpression was found in 96% of NMIBC and 52% of MIBC samples, as well as in two bladder cancer cell lines. Altered expression of miRNAs supported their oncogene or tumour-suppressor gene status. In univariate analysis, high expression levels of PTCH2, miRNA-92A, miRNA-19A, and miRNA-20A were associated with poorer overall survival in MIBC (P=0.02, P=0.012, P=0.047, and P=0.036, respectively). CONCLUSION We observed constitutive activation of the Hh pathway in most NMIBC and about 50% of MIBC. We also found that some protein-coding genes and miRNAs involved in the Hh pathway may have prognostic value at the individual level.
Collapse
Affiliation(s)
- G Pignot
- Department of Urology, Service d'Urologie, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du Faubourg Saint Jaques, Paris F-75014, France.
| | | | | | | | | | | | | | | |
Collapse
|